Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 7:12 AM ET

Healthcare Equipment and Supplies

Company Overview of Interpace Diagnostics Corporation

Company Overview

Interpace Diagnostics Corporation operates a molecular diagnostics company that helps physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG platform. Its PathfinderTG platform uses advanced clinical algorithms to accurately stratify patients according to risk of cancer by assessing panels of DNA abnormalities in patients who have lesions (i.e., cysts or solid masses) with potential for cancer. Interpace Diagnostics Corporation was formerly known as RedPath Integrated Pathology, Inc. The company was founded in 2004 and is headquartered in Parsippany, New Jersey. As of October 31, 2014, Interpace Diagnostics Corporation ope...

300 Interpace Parkway

Morris Corporate Center 1

Building A

Parsippany, NJ 07054

United States

Founded in 2004



Key Executives for Interpace Diagnostics Corporation

Founder and Chief Scientific Officer
Chief Financial Officer
Director of Sales & Marketing
Director of Cytology & Clinical Chemistry and Associate Molecular Laboratory Director
Director of Clinical Development
Compensation as of Fiscal Year 2015.

Interpace Diagnostics Corporation Key Developments

RedPath Integrated Pathology Announces Departure of Dennis Smith as President and CEO at the End of November 2014

PDI Inc. has acquired RedPath Integrated Pathology that tests for gastrointestinal, pancreatic and other cancer risks. Dennis Smith, M.D., RedPath president and CEO is departing at the end of the November 2014 but will remain an adviser to PDI's board.

RedPath Integrated Pathology, Inc. Launches Accucea Chemistry Test for Pancreatic Cyst Patients

RedPath Integrated Pathology, Inc. announced the launch of a new, patent-pending, customized test to accurately measure carcinoembryonic antigen in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA(TM) provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests. When the amount of pancreatic cyst fluid is limited and CEA testing is prescribed, CEA can be analyzed in diluted fluid. However, dilution of cyst fluid can significantly impact the analytical accuracy of the resulting CEA measurements. RedPath has solved this problem by creating AccuCEA, which provides CEA measurements in diluted cyst fluid that are true to their corresponding neat (undiluted) cyst fluid CEA measurements. Results of the study documenting the accuracy of AccuCEA were presented at the 2013 Digestive Disease Week meeting.

Similar Private Companies By Industry

Company Name Region
Viper Technologies, LLC United States
Kypha Inc. United States
Monster Medic, Inc. United States
ALine, Inc. United States
NEA Optical, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Interpace Diagnostics Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at